Effect of anti-VEGF treatment on choroidal thickness over time in patients with neovascular age-related macular degeneration

European Journal of Ophthalmology

Volumn 24, Issue 6, 2014, Pages 897-903

  McDonnell, Emma C ^a   Heussen, Florian M ^a,b   Ruiz Garcia, Humberto ^a   Ouyang, Yanling ^a,b   Narala, Ramsudha ^a   Walsh, Alexander C ^a   Sadda, Srinivas R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Age related macular degeneration; Choriocapillaris; Image analysis; Optical coherence tomography

Indexed keywords

VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; BRUCH MEMBRANE; CHOROID; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEOGRAPHIC ATROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SUBFOVEAL CHOROIDAL THICKNESS; VISIBILITY; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR DEGENERATION; OPTICAL COHERENCE TOMOGRAPHY; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VERY ELDERLY; WET MACULAR DEGENERATION;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; CHOROID; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; ORGAN SIZE; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84907808019     PISSN: 11206721     EISSN: None     Source Type: Journal    
DOI: 10.5301/ejo.5000509     Document Type: Article

References (24)

1. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-31.
2. Brown DM, Kaiser PK, Michels M, et al; ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44.
3. Grisanti S, Tatar O. The role of vascular endothelial growth factor and other endogenous interplayers in age-related macular degeneration. Prog Retin Eye Res 2008;27:372-90.
4. Shima C, Sakaguchi H, Gomi F, et al. Complications in patients after intravitreal injection of bevacizumab. Acta Oph-thalmol. 2008;86:372-6.
5. Bhutto IA, McLeod DS, Hasegawa T, et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration. Exp Eye Res. 2006;82:99-110.
6. Spaide R F. Age-related choroidal atrophy. Am J Ophthalmol. 2009;147:801-10.
7. Spaide R F. Enhanced depth imaging optical coherence tomography of retinal pigment epithelial detachment in age-related macular degeneration. Am J Ophthalmol. 2009;147: 644-52.
8. Margolis R, Spaide R F. A pilot study of enhanced depth imaging optical coherence tomography of the choroid in normal eyes. Am J Ophthalmol. 2009;147:811-5.
9. Spaide R F, Koizumi H, Pozzoni MC, Pozonni MC. Enhanced depth imaging spectral-domain optical coherence tomography [erratum 2009;148:325]. Am J Ophthalmol. 2008;146: 496-500.
10. Lujan BJ, Rosenfeld PJ, Gregori G, et al. Spectral domain optical coherence tomographic imaging of geographic atrophy. Ophthalmic Surg Lasers Imaging. 2009;40:96-101.
11. Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide R F. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology. 2010;117:1792-9.
12. Maruko I, Iida T, Sugano Y, et al. Subfoveal choroidal thickness after treatment of Vogt-Koyanagi-Harada disease. Retina. 2011;31:510-7.
13. Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photody-namic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol. 2011;151:594-603.
14. Vance SK, Imamura Y, Freund KB. The effects of sildenafil citrate on choroidal thickness as determined by enhanced depth imaging optical coherence tomography. Retina. 2011; 31:332-5.
15. Imamura Y, Fujiwara T, Margolis R, Spaide R F. Enhanced depth imaging optical coherence tomography of the cho-roid in central serous chorioretinopathy. Retina. 2009;29: 1469-73.
16. Ikuno Y, Kawaguchi K, Nouchi T, Yasuno Y. Choroidal thickness in healthy Japanese subjects. Invest Ophthalmol Vis Sci. 2010;51:2173-6.
17. Delaey C, Van De Voorde J. Regulatory mechanisms in the retinal and choroidal circulation. Ophthalmic Res. 2000;32: 249-56.
18. Boltz A, Luksch A, Wimpissinger B, et al. Choroidal blood flow and progression of age-related macular degeneration in the fellow eye in patients with unilateral choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010;51: 4220-5.
19. Zhu Q, Ziemssen F, Henke-Fahle S, et al. Vitreous levels of bevacizumab and vascular endothelial growth factor–A in patients with choroidal neovascularization. Ophthalmology. 2008;115:1750-5.
20. Tong J-P, Chan W-M, Liu DTL, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol. 2006; 141:456-62.
21. Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth factor and pigment epithelium–derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol. 2009;148:718-24.
22. Chan W-M, Lai TYY, Chan K-P, et al. Changes in aqueous vascular endothelial growth factor and pigment epithelial–derived factor levels following intravitreal bevacizumab injections for choroidal neovascularization secondary to age-related mac-ular degeneration or pathologic myopia. Retina. 2008; 28: 1308-13.
23. Le Y-Z, Bai Y, Zhu M, Zheng L. Temporal requirement of RPE-derived VEGF in the development of choroidal vascula-ture. J Neurochem. 2010;112:1584-92.
24. Hu W, Criswell MH, Fong S-L, et al. Differences in the temporal expression of regulatory growth factors during cho-roidal neovascular development. Exp Eye Res. 2009;88: 79-91.